Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04885686
Other study ID # EndoPOP
Secondary ID 2021-A00065-36
Status Completed
Phase N/A
First received
Last updated
Start date June 22, 2021
Est. completion date June 11, 2022

Study information

Verified date July 2022
Source Septodont
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a post-marketing performance and safety study, designed as a comparative, prospective, multicenter, simple-blind, randomized clinical trial. 300 subjects requiring a primary or a secondary root canal treatment will be enrolled in 2 groups (150 in each group). The aim of the study is to demonstrate the superiority of the hydrocortisone-containing root canal sealer Endomethasone N RCS, compared to the hydrocortisone-free root canal sealer Endomethasone SP RCS, with regard to reduction of the maximum post-operative spontaneous pain during the 7 days following the root canal treatment. Root canal treatment procedures will be in accordance with the allocation by randomisation of Endomethasone N RCS or Endomethasone SP RCS. The spontaneous and the Masticatory pain will be record at predefined times, a phone call will be done at 48h and a visit will be realized at day 7 (max Day 14).


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date June 11, 2022
Est. primary completion date July 6, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult male or female (age = 18 years); - Patient requiring root canal treatment or retreatment; - Patient who will need a single visit for the root canal therapy, for a mature molar or second premolar, with or without pre-operative pain - Patient who received information and gave written consent (signed informed consent form); - Subject affiliated to a health insurance system, or is a beneficiary (art. L.1121-11, Code of Public Health, France). Exclusion Criteria: - Pulpotomy or pulpectomy performed at a prior visit; - Tooth with apical calcification (sealer unable to reach the root apex); - Tooth with suspected root perforation; - Immature tooth (too wide root apex requiring an apexification); - Other dental treatment ongoing or scheduled within the study period; - At least one symptomatic tooth among those that are not included in this study - Known hypersensitivity to steroids, local anesthetics, or any component of study medical devices; - Subject using long term anti-inflammatory drugs; - Use of illicit substances during the 48h before the first visit (cannabis, cocaine…); - Presence of any significant medical finding or significant history such as uncontrolled systemic diseases that may impact the safety, the interpretation of the results and/or the participation of the subject in the study according to the opinion of the investigator; - Subject who cannot be contacted in case of emergency (phone number); - Simultaneous participation in another clinical trial or subject still within the exclusion period of a previous clinical trial; - Vulnerable subjects (art. L.1121-5 and L.1122-1-2, Code of Public Health, France; art. 66 of the Regulation (EU) 2017/745 on medical devices)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Endomethasone N RCS
Root canal sealer
Endomethasone SP RCS
Root canal sealer

Locations

Country Name City State
France Cabinet dentaire Agon-Coutainville
France Cabinet dentaire Betton
France Cabinet dentaire Chartres-de-Bretagne
France Cabinet Dentaire Cherbourg
France Cabinet dentaire Cherbourg
France Cabinet dentaire Dinan
France Cabinet dentaire Équeurdreville-Hainneville
France Cabinet dentaire Lamballe
France Centre de santé dentaire Chevaleret Paris
France Centre dentaire Flandre Paris
France Cabinet dentaire Pluguffan
France Cabinet dentaire Quimper
France Cabinet dentaire Rennes
France Cabinet dentaire Saint-Aubin-de-Médoc
France Cabinet dentaire Tinténiac

Sponsors (2)

Lead Sponsor Collaborator
Septodont Slb Pharma

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum post-operative pain using a visual analogue scale (VAS : 0-100) The pain is assessed by patients in a diary using a Visual Analogue Scale (VAS: 0-100 mm; 0 no pain - 100 maximum pain) at different times after endodontic treatment (at the end of the root canal obturation, 3h, 6h 12h, 24h, Day 2, Day 3, Day 4 Day 5, Day 5, Day 7). The maximum pain felt will be compared between the 2 groups. from the end of the root canal treatment (Day 0) to Day 7
Secondary Spontaneous pain intensity The spontaneous pain intensity measured using a Visual Analogue Scale (VAS: 0-100mm; 0 no pain - 100 maximum pain) from the end of the root canal treatment (Day 0) to Day 7
Secondary Occurrence of spontaneous pain flare-ups The occurrence of spontaneous pain flare-ups is an increase of 20 mm in the Visual Analogue Scale (VAS: 0-100mm; 0 no pain-100 maximum pain) between 2 consecutive measurements after the firsts 3 days. From Day 3 to Day7
Secondary Masticatory pain intensity The masticatory pain intensity measured using a Visual Analogue Scale (VAS: 0-100mm; 0 no pain -100 maximum pain) assessed twice a day from Day 0 to Day3 (lunch and dinner), and once a day from Day 4 to Day7 (dinner). from the end of the root canal treatment (Day 0) to Day 7
Secondary Maximum Masticatory pain intensity using a visual analogue scale (VAS : 0-100mm) The maximum masticatory pain intensity measured Visual Analogue Scale (VAS: 0-100mm; 0 no pain- 100 maximum pain) from the end of the root canal treatment (Day 0) to Day 7
Secondary Use of oral pain treatment Patients reported the consumption of analgesic treatment in a diary. The proportion of patients who took oral pain medication and the treatment categories will be compared between the 2 groups. from the end of the root canal treatment (Day 0) to Day 7
Secondary Quality of life with the OHIP-17 questionnaire (score 0-68) The answers and the total score from the OHIP 17-items questionnaire (measured at baseline and 48 h) will be compared between 2 groups. Score between 0 and 68, 0 means no dental issuel, 68 all the issues very often. baseline and from 48 to 72 hours
Secondary Adverse events Adverse events reported by patients on a diary from Day 0 to Day 7 and adverse events clinically observed by the dental surgeon at each follow-up visit will be used to assess the safety of root canal sealers and endodontic procedures from the inclusion (Day 0) to Day 7
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04757753 - Root Canal Obturation With a Ready-to-use Root Canal Sealer (PA1704) Versus BioRootâ„¢ RCS: a Randomized Controlled Trial N/A
Completed NCT04935736 - Postoperative Pain After Root Canal Obturation With Sealer Containing Prednisolone. N/A
Completed NCT01728532 - Open, Multicentric Trial Evaluating the Efficacy and the Clinical Tolerance of PA0903 as Root Canal Sealer N/A
Completed NCT04753138 - Outcome of SBO With Calcium Silicate Sealer vs WVC With Resin Based Sealer N/A
Recruiting NCT05247138 - Measurement of the Clinical and Radiological Performance Impact of the Root Canal Treatment With BioRootTM RCS.
Completed NCT03732170 - Root Canal Treatment With TotalFill® Bioceramic Sealer and AH Plus® Sealer N/A
Completed NCT03874949 - Pain After Root Canal Obturation With Sealer Containing or Not 1% Enoxolone N/A